220
Ph cancers
|
Age (< 65/ ≥65 years)
|
499/480
|
0.131
|
Gender (male/female)
|
454/615
|
0.335
|
Tumor size (< 3/ ≥3 cm)
|
555/488
|
0.358
|
Well/Moderate/poor
Differentiation
|
615/555/411
|
0.155
|
T stage
(T1 + T2/T3)
|
488/454
|
0.105
|
Lymph nodes metastasis (N0/N1/N2)
|
565/418/185
|
0.004
|
8th AJCC stage
(I + II /III + IV)
|
360/273
|
0.017
|
Perineural invasion (absent/present)
|
880/545
|
0.298
|
Vascular permeation
(absent/present)
|
565/350
|
0.005
|
CA19–9 level
(< 37 U/ml/ ≥37 U/ml)
|
666/450
|
0.171
|
PLM
| | |
absent/present
|
586/365
|
0.039
|
131
Pbt cancers
|
Age (< 65/ ≥65 years)
|
381/300
|
0.111
|
Gender (male/female)
|
395/340
|
0.439
|
Tumor size (< 3/ ≥3 cm)
|
530/320
|
0.023
|
Well/Moderate/poor
Differentiation
|
400/280/273
|
0.070
|
T stage
(T1 + T2/ T3 + T4)
|
418/320
|
0.016
|
Lymph nodes metastasis (N0/N1/N2)
|
360/259/234
|
0.007
|
8th AJCC stage
(I + II /III + IV)
|
499/273
|
0.001
|
Perineural invasion (absent/present)
|
360/333
|
0.104
|
Vascular permeation
(absent/present)
|
400/265
|
0.009
|
CA19–9 level
(< 37 U/ml/ ≥37 U/ml)
|
468/331
|
0.099
|
PLM
|
432/275
|
0.001
|
absent/present
| | |